Connect Biopharma Holdings (CNTB) Income from Non-Controlling Interests (2024 - 2026)

Connect Biopharma Holdings (CNTB) has reported Income from Non-Controlling Interests for 3 consecutive years, with -$4000.0 the latest figure, recorded in Q1 2026.

• Quarterly Income from Non-Controlling Interests fell 300.0% year-over-year to -$4000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$5000.0 (down 350.0% YoY) and the FY2025 annual result came in at -$2000.0, down 116.67% from the prior year.
• Income from Non-Controlling Interests advanced to -$4000.0 in Q1 2026 per CNTB's latest filing, from -$6000.0 in the prior quarter.
• Over the last five years, Income from Non-Controlling Interests for CNTB reached as high as $11000.0 in Q3 2025 and fell as low as -$6000.0 in Q2 2025.
• A 3-year average of $750.0 and a median of $0.0 in 2024 frame the typical range for Income from Non-Controlling Interests.
• The largest YoY upside for Income from Non-Controlling Interests was 111.11% in 2025 against a maximum downside of 700.0% in 2025.
• Year by year, Income from Non-Controlling Interests stood at $1000.0 in 2024, then plunged by 700.0% to -$6000.0 in 2025, then jumped by 33.33% to -$4000.0 in 2026.
• According to Business Quant data, Income from Non-Controlling Interests over the past three periods registered -$4000.0, -$6000.0, and $11000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.